Pegloticase: In treatment-refractory chronic gout

Drugs

Volumn 71, Issue 16, 2011, Pages 2179-2192

  Lyseng Williamson, Katherine A ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Evaluations; Gout

Indexed keywords

COLCHICINE; FEXOFENADINE; HYDROCORTISONE; PARACETAMOL; PEGLOTICASE; PLACEBO; URIC ACID;

ANAPHYLAXIS; CONSTIPATION; CONTUSION; CORTICOSTEROID THERAPY; DEEP VEIN THROMBOSIS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ECCHYMOSIS; GOUT; GOUT FLARE; HEART ARREST; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; INJECTION SITE REACTION; LONG TERM CARE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PHARMACOLOGICAL PARAMETERS; PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFRACTORY CHRONIC GOUT; REVIEW; RHINOPHARYNGITIS; SINGLE DRUG DOSE; THORAX PAIN; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; URIC ACID BLOOD LEVEL; VOMITING;

DRUG RESISTANCE; GOUT; GOUT SUPPRESSANTS; HUMANS; INFUSIONS, INTRAVENOUS; MODELS, BIOLOGICAL; POLYETHYLENE GLYCOLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; URATE OXIDASE;

EID: 80155159966     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11202830-000000000-00000     Document Type: Review

References (23)

1. Richette P, Bardin T. Gout. Lancet 2010 Jan 23; 375 (9711): 318-28
2. Schlesinger N. Difficult-to-treat gouty arthritis: a disease warranting better management. Drugs 2011; 71 (11): 1413-9
3. Sherman MR, Saifer MG, Perez-Ruiz F. PEG-uricase in the management of treatment-resistant gout and hyperuricemia. Adv Drug Deliv Rev 2008 Jan 3; 60 (1): 59-68 (Pubitemid 350186186)
4. Fels E, Sundy JS. Refractory gout: what is it and what to do about it? Curr Opin Rheumatol 2008; 20 (2): 198-202 (Pubitemid 351339893)
5. Edwards NL. Treatment-failure gout: a moving target. Arthritis Rheum 2008 Sep; 58 (9): 2587-90
6. Li-Yu J, Clayburne G, Sieck M, et al. Treatment of chronic gout: can we determinewhen urate stores are depleted enough to prevent attacks of gout? J Rheumatol 2001; 28: 577-80 (Pubitemid 32202663)
7. KRYSTEXXA(pegloticase) injection for intravenous injection: US prescribing information. East Brunswick (NJ): Savient Pharmaceuticals, Inc., 2010 Sep
8. Sundy JS, Ganson NJ, Kelly SJ, et al. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum 2007 Mar; 56 (3): 1021-8 (Pubitemid 46399452)
9. Sundy JS, Becker MA, Baraf HS, et al. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. Arthritis Rheum 2008 Sep; 58 (9): 2882-91
10. Sundy JS, BarafHS, YoodRA, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA 2011 Aug 17; 306 (7): 711-20
11. Application number 1252930: clinical pharmacology and biopharmaceutics review(s). Silver Spring (MD): FDA Center for Drug Evaluation and Research, 2009 Feb 5
12. Kelly SJ, Delnomdedieu M, Oliverio MI, et al. Diabetes insipidus in uricase-deficient mice: a model for evaluating therapy with poly(ethylene glycol)-modified uricase. J Am Soc Nephrol 2001 May; 12 (5): 1001-9 (Pubitemid 32378341)
13. Baraf HS, Matsumoto AK, Maroli AN, et al. Resolution of gouty tophi after twelve weeks of pegloticase treatment. Arthritis Rheum 2008 Nov; 58 (11): 3632-4
14. Armstrong JK, Hempel G, Koling S, et al. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 2007 Jul 1; 110 (1): 103-11 (Pubitemid 46986423)
15. Elitek(rasburicase) powder for solution, for intravenous infusion: US prescribing information. Bridgewater (NJ): sanofi-aventis U.S. LLC, 2010 Feb
16. Singh JA, Yang S, Strand V, et al. Validation of pain and patient global scales in chronic gout: data from two randomised controlled trials.Ann RheumDis 2011 Jul; 70 (7): 1277-81
17. Lubeck D. Patient-reported outcomes and their role in the assessment of rheumatoid arthritis. Pharmacoeconomics 2004; 22 Suppl. 1: 27-38 (Pubitemid 38269931)
18. Wells G, Tugwell P, Kraag GR, et al. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993; 20 (3): 557-60 (Pubitemid 23102493)
19. Sundy JS, Baraf HSB, Gutierrez-Urena SR, et al. Chronic use of pegloticase: safety and efficacy update [abstract no. 1113].ArthritisRheum 2009Oct; 60 (10 Suppl.). Plus poster presented at the American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting; 2009 Oct 16-21; Philadelphia (PA)
20. Hamburger SA, Lipsky P, Khanna D, et al. Safety and efficacy of long-term pegloticase (KRYSTEXXA) treatment in adult patients with chronic gout refractory to conventional therapy [abstract no. OP0113]. 12th Annual Congress of the European League Against Rheumatism; 2011 May 25-28; London
21. Antiplatelet Trialists' Collaboration. Collaboration overview of randomized trials of antiplatelet therapy. BMJ 1994; 308 (6921): 81-106
22. Somberg JC, Cvetanovic I, Rosario-Jansen T, et al. Pegloticase does not cause QT interval prolongation [abstract no. 94]. J Investig Med 2011 Apr; 59 (4): 720
23. Sampson HA, Munoz-Furlong A, Campbell RI, et al. Second symposium on the definition and management of anaphylaxis. Ann Emerg Med 2006; 47 (6): 373-80